000126860 001__ 126860
000126860 005__ 20241125101154.0
000126860 0247_ $$2doi$$a10.3390/ijms241310713
000126860 0248_ $$2sideral$$a134223
000126860 037__ $$aART-2023-134223
000126860 041__ $$aeng
000126860 100__ $$0(orcid)0000-0002-0036-6630$$aAlgarate, Sonia$$uUniversidad de Zaragoza
000126860 245__ $$aPersistence of Anti-S1 IgG against SARS-CoV-2 eight months after the Booster dose of Vaccine in naive and previously infected healthcare workers
000126860 260__ $$c2023
000126860 5060_ $$aAccess copy available to the general public$$fUnrestricted
000126860 5203_ $$aOur aim was to evaluate the immune response of healthcare workers included in the RIPOVAC study, after receiving a booster dose (third dose), in terms of intensity and persistence of induced antibodies. In the second phase of the RIPOVAC study, between December 2021 and January 2022, eight months after the second dose, 389 voluntary, immunocompetent, non-pregnant healthcare workers received a booster dose of SARS-CoV-2 vaccine, and a serum sample was obtained. Two groups of patients were established: with and without previous SARS-CoV-2 infection. In order to quantify anti-S1 IgG (AU/mL) we used CMIA (Abbott). All of the health workers were anti-S IgG positive 8 months after receiving the booster dose of the vaccine, with a mean of 17,040 AU/mL. In 53 patients without previous infection, antibody levels increased by a mean of 10,762 AU/mL. This figure is seven times higher than the one produced after the second dose (1506 AU/mL). The booster dose produces a robust elevation of the antibody level, which persists at 8 months, with levels significantly higher than those reached after the second dose, which allow one to predict a persistence of more than one year. The study demonstrates the efficacy of the booster dose of anti-SARS-CoV-2 vaccines.
000126860 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000126860 590__ $$a4.9$$b2023
000126860 592__ $$a1.179$$b2023
000126860 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b66 / 313 = 0.211$$c2023$$dQ1$$eT1
000126860 593__ $$aMedicine (miscellaneous)$$c2023$$dQ1
000126860 591__ $$aCHEMISTRY, MULTIDISCIPLINARY$$b68 / 231 = 0.294$$c2023$$dQ2$$eT1
000126860 593__ $$aPhysical and Theoretical Chemistry$$c2023$$dQ1
000126860 593__ $$aComputer Science Applications$$c2023$$dQ1
000126860 593__ $$aInorganic Chemistry$$c2023$$dQ1
000126860 593__ $$aSpectroscopy$$c2023$$dQ1
000126860 593__ $$aOrganic Chemistry$$c2023$$dQ1
000126860 593__ $$aMolecular Biology$$c2023$$dQ2
000126860 593__ $$aCatalysis$$c2023$$dQ2
000126860 594__ $$a8.1$$b2023
000126860 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000126860 700__ $$aSerrano, Laura
000126860 700__ $$aBueno, Jessica$$uUniversidad de Zaragoza
000126860 700__ $$aHerrero-Cortina, Beatriz
000126860 700__ $$aAlvarado, Elena
000126860 700__ $$aGonzález-Barriga, María T.
000126860 700__ $$aDucons, María
000126860 700__ $$aMontero-Marco, Jesica
000126860 700__ $$aArnal, Sara
000126860 700__ $$aAcha, Beatriz$$uUniversidad de Zaragoza
000126860 700__ $$aRiesgo, María
000126860 700__ $$aTaboada, Ana
000126860 700__ $$aSanz-Burillo, Pilar
000126860 700__ $$aYuste, Cristina
000126860 700__ $$0(orcid)0000-0001-5134-1006$$aBenito, Rafael$$uUniversidad de Zaragoza
000126860 700__ $$aRIPOVAC Study Group
000126860 7102_ $$11006$$2255$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Enfermería
000126860 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología
000126860 773__ $$g24, 13 (2023), 10713 [7 pp.]$$pInt. j. mol. sci.$$tInternational Journal of Molecular Sciences$$x1661-6596
000126860 8564_ $$s1307339$$uhttps://zaguan.unizar.es/record/126860/files/texto_completo.pdf$$yVersión publicada
000126860 8564_ $$s2526912$$uhttps://zaguan.unizar.es/record/126860/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000126860 909CO $$ooai:zaguan.unizar.es:126860$$particulos$$pdriver
000126860 951__ $$a2024-11-22-12:08:33
000126860 980__ $$aARTICLE